Efficacy and Safety of ddEC-ddP for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Conditions: HER2-negative Breast Cancer; Neoadjuvant Chemotherapy Interventions: Drug: Epirubicin; Drug: Cyclophosphamid; Drug: Docetaxel; Drug: Paclitaxel Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | HER2 | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Taxotere